



DAFTAR PUSTAKA

- CarrascoSánchez, F.J., Galisteo-Almeda, L., Páez-Rubio, I., Martínez-Marcos, F.J., Camacho-Vázquez, C., Ruiz-Frutos, C., *et al.* (2011). Prognostic value of cystatin C on admission in heart failure with preserved ejection fraction. *J. Card. Fail.* 17 : 31–38.
- Armstrong, P.W., Pieske, B., Anstrom, K.J., Ezekowitz, J., Hernandez, A.F., Butler, J., *et al.* (2020). Vericiguat in patients with heart failure and reduced ejection fraction. *N. Engl. J. Med.*
- Arumugam, S., Sreedhar, R., Thandavarayan, R.A., Karuppagounder, V., Krishnamurthy, P., Suzuki, K., *et al.* (2016). Angiotensin receptor blockers: Focus on cardiac and renal injury. *Trends Cardiovasc. Med.* 26 : 221–228.
- Bargnoux, A.S., Piéroni, L., Cristol, J.P., Kuster, N., Delanaye, P., Carlier, M.C., *et al.* (2017). Multicenter evaluation of Cystatin C measurement after assay standardization. *Clin. Chem.* 63.
- Berecek, K.H., King, S.J., & Wu, J.N. (2018). Angiotensin-converting enzyme and converting enzyme inhibitors, yn: *Cellular and Molecular Biology of the Renin-Angiotensin System.*
- Bloom, M.W., Greenberg, B., Jaarsma, T., Januzzi, J.L., Lam, C.S.P., Maggioni, A.P., *et al.* (2017). Heart failure with reduced ejection fraction. *Nat. Rev. Dis. Prim.*
- Brahmbhatt, D.H., & Cowie, M.R. (2018). Heart failure: classification and pathophysiology. *Med. (United Kingdom)* 46 : 587–593.
- Carrasco-Sánchez, F.J., Galisteo-Almeda, L., Páez-Rubio, I., Martínez-Marcos, F.J., Camacho-Vázquez, C., Ruiz-Frutos, C., *et al.* (2011). Prognostic value of cystatin C on admission in heart failure with preserved ejection fraction. *J. Card. Fail.* 17 : 31–38.
- Castiglione, V., Aimo, A., Vergaro, G., Saccaro, L., Passino, C., & Emdin, M. (2022). Biomarkers for the diagnosis and management of heart failure. *Heart Fail. Rev.*
- Chew, J.S.C., Saleem, M., Florkowski, C.M., & George, P.M. (2008). Cystatin C-- a paradigm of evidence based laboratory medicine. *Clin. Biochem. Rev.* 29.
- Cobas (2020). Elecsys proBNP II Packungsbeilage V1.0 : 1–8.
- Cystatin, T. (2023). Cysc2 04975901191 06729371190 2–5.
- Dahlan, M.S. (2019). Besar sampel dalam penelitian kedokteran dan kesehatan (5th ed.). Jakarta : Epidemiologi Indonesia.
- Diagnostics, S. (2018). Recommended total allowable error limits, Sun Diagnostics.
- Doshi, R., Dhawan, T., Rendon, C., Rodriguez, M.A., Al-khafaji, J.F., Taha, M., *et*



- al. (2020). Incidence and implications of acute kidney injury in patients hospitalized with acute decompensated heart failure. *Intern. Emerg. Med.* 15 : 421–428.
- Ellison, D.H., & Felker, G.M. (2017). Diuretic Treatment in Heart Failure. *N. Engl. J. Med.* 377 : 1964–1975.
- Grubb, A., Blirup-Jensen, S., Lindström, V., Schmidt, C., Althaus, H., & Zegers, I. (2010). First certified reference material for Cystatin C in human serum ERM-DA471/IFCC. *Clin. Chem. Lab. Med.* 48.
- Harper, A.R., Patel, H.C., & Lyon, A.R. (2018). Heart failure with preserved ejection fraction. *Clin. Med. J. R. Coll. Physicians London.*
- Hsu, J.J., Ziaecian, B., & Fonarow, G.C. (2017). Heart Failure With Mid-Range (Borderline) Ejection Fraction. *JACC Hear. Fail.* 5 : 763–771.
- Hubers, S.A., & Brown, N.J. (2016). Combined Angiotensin Receptor Antagonism and Nephilysin Inhibition. *Circulation* 133 : 1115–1124.
- Inamdar, Arati, & Inamdar, Ajinkya (2016). Heart Failure: Diagnosis, Management and Utilization. *J. Clin. Med.*
- Ix, J.H., Shlipak, M.G., Chertow, G.M., & Whooley, M.A. (2007). Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: Data from the Heart and Soul Study. *Circulation* 115 : 173–179.
- Javaheri, S. (2016). Heart failure, yn: *The Curated Reference Collection in Neuroscience and Biobehavioral Psychology.*
- Kemp, C.D., & Conte, J. V. (2012). The pathophysiology of heart failure. *Cardiovasc. Pathol.* 21 : 365–371.
- Khan, M.S., Shahid, I., Bennis, A., Rakisheva, A., Metra, M., & Butler, J. (2024). Global epidemiology of heart failure. *Nat. Rev. Cardiol.* 21 : 717–734.
- Kreslová, M., Jehlička, P., Sýkorová, A., Rajdl, D., Klásková, E., Prokop, P., *et al.* (2022). Circulating Serum Cystatin C as an Independent Risk Biomarker for Vascular Endothelial Dysfunction in Patients with COVID-19-Associated Multisystem Inflammatory Syndrome in Children (MIS-C): A Prospective Observational Study. *Biomedicines* 10.
- Kurmani, S., & Squire, I. (2017). Acute Heart Failure: Definition, Classification and Epidemiology. *Curr. Heart Fail. Rep.*
- Lainscak, M., Pelliccia, F., Rosano, G., Vitale, C., Schiariti, M., Greco, C., *et al.* (2015). Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone. *Int. J. Cardiol.*
- Lee, M., Saver, J.L., Huang, W.H., Chow, J., Chang, K.H., & Ovbiagele, B. (2010). Impact of elevated cystatin C level on cardiovascular disease risk in



- predominantly high cardiovascular risk populations: A meta-analysis. *Circ. Cardiovasc. Qual. Outcomes* 3.
- Lekawanvijit, S., & Krum, H. (2014). Cardiorenal syndrome: Acute kidney injury secondary to cardiovascular disease and role of protein-bound uraemic toxins. *J. Physiol.*
- Levin, A., & Lan, J.H. (2016). Cystatin C and Cardiovascular Disease. *J. Am. Coll. Cardiol.* 68 : 946–948.
- Lledó, A.G., Romo, E.M.G., & Delgado, J.G. (2019). Chronic heart failure. *Med.*
- Lopes, R.D., Rordorf, R., De Ferrari, G.M., Leonardi, S., Thomas, L., Wojdyla, D.M., *et al.* (2018). Digoxin and Mortality in Patients With Atrial Fibrillation. *J. Am. Coll. Cardiol.* 71 : 1063–1074.
- Lou, B., Luo, Y., Zhang, H., Wu, H., Jiang, G.T., Liu, H., *et al.* (2022). Association between Cystatin C and Cardiac Function in Acute Myocardial Infarction Patients: A Real-World Analysis. *Dis. Markers* 2022.
- MacDonald, M.R., Tay, W.T., Teng, T.K., Anand, I., Ling, L.H., Yap, J., *et al.* (2020). Regional Variation of Mortality in Heart Failure With Reduced and Preserved Ejection Fraction Across Asia: Outcomes in the ASIAN-HF Registry. *J. Am. Heart Assoc.* 9.
- Mann, D.L., & Chakinala, M. (2018). Harrison's Principles of Internal Medicine 20.
- Metra, M., & Teerlink, J.R. (2017). Heart failure. *Lancet.*
- Mueller, L., & Pruemper, C. (2016). Performance in Measurement of Serum Cystatin C by Laboratories Participating in the College of American Pathologists 2014 CYS Survey. *Arch. Pathol. Lab. Med.* 140 : 207–207.
- Murphy, S.P., Kakkar, R., McCarthy, C.P., & Januzzi, J.L. (2020). Inflammation in Heart Failure: JACC State-of-the-Art Review. *J. Am. Coll. Cardiol.* 75 : 1324–1340.
- Onopiuk, A., Tokarzewicz, A., & Gorodkiewicz, E. (2015). Cystatin C : A Kidney Function Biomarker, 1af ed, Advances in Clinical Chemistry. Elsevier Inc.
- Orso, F., Fabbri, G., & Maggioni, A. Pietro (2017). Epidemiology of heart failure, yn: *Handbook of Experimental Pharmacology.*
- Ponikowski, P., Voors, A.A., Anker, S.D., Bueno, H., Cleland, J.G.F., Coats, A.J.S., *et al.* (2016). 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur. Heart J.*
- Rangaswami, J., Bhalla, V., Blair, J.E.A., Chang, T.I., Costa, S., Lentine, K.L., *et al.* (2019). Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies: A Scientific Statement From the American Heart Association. *Circulation.*



- Redfield, M.M. (2016). Heart failure with preserved ejection fraction. *N. Engl. J. Med.*
- Roger, V.L. (2016). Heart Failure, yn: *International Encyclopedia of Public Health.*
- Rogers, C., & Bush, N. (2015). Heart Failure: Pathophysiology, Diagnosis, Medical Treatment Guidelines, and Nursing Management. *Nurs. Clin. North Am.* 50 : 787–799.
- Satizabal, C.L., Beiser, A.S., Chouraki, V., Chêne, G., Dufouil, C., & Seshadri, S. (2016). Incidence of Dementia over Three Decades in the Framingham Heart Study. *N. Engl. J. Med.* 374 : 523–532.
- Schwinger, R.H.G. (2021). Pathophysiology of heart failure. *Cardiovasc. Diagn. Ther.* 11 : 263–276.
- Selcuk, H., Selcuk, M.T., Maden, O., Balci, K.G., Balci, M.M., Tekeli, S., *et al.* (2018). The impact of admission cystatin C levels on in-hospital and three-year mortality rates in acute decompensated heart failure. *Cardiovasc. J. Afr.* 29 : 305–309.
- Shah, K.S., Xu, H., Matsouaka, R.A., Bhatt, D.L., Heidenreich, P.A., Hernandez, A.F., *et al.* (2017). Heart Failure With Preserved, Borderline, and Reduced Ejection Fraction: 5-Year Outcomes. *J. Am. Coll. Cardiol.*
- Sousa-Uva, M., Neumann, F.J., Ahlsson, A., Alfonso, F., Banning, A.P., Benedetto, U., *et al.* (2019). 2018 ESC/EACTS Guidelines on myocardial revascularization. *Eur. J. Cardio-thoracic Surg.*
- Stoka, V., Vasiljeva, O., Nakanishi, H., & Turk, V. (2023). The Role of Cysteine Protease Cathepsins B, H, C, and X/Z in Neurodegenerative Diseases and Cancer. *Int. J. Mol. Sci.* 24 : 15613.
- Sullivan, R.D., & Gladysheva, I.P. (2022). Advances and Challenges in Diagnosis and Management of Heart Failure. *Diagnostics.*
- Takeda, A., Martin, N., Taylor, R.S., & Taylor, S.J. (2019). Disease management interventions for heart failure. *Cochrane Database Syst. Rev.* 2019.
- Verma, A., Kalman, J.M., & Callans, D.J. (2017). Treatment of Patients With Atrial Fibrillation and Heart Failure With Reduced Ejection Fraction. *Circulation* 135 : 1547–1563.
- West, M., Kirby, A., Stewart, R.A., Blankenberg, S., Sullivan, D., White, H.D., *et al.* (2022). Circulating Cystatin C Is an Independent Risk Marker for Cardiovascular Outcomes, Development of Renal Impairment, and Long-Term Mortality in Patients With Stable Coronary Heart Disease: The LIPID Study. *J. Am. Heart Assoc.* 11.
- White, C.A., Rule, A.D., Collier, C.P., Akbari, A., Lieske, J.C., Lepage, N., *et al.* (2011). The impact of interlaboratory differences in Cystatin C assay measurement on Glomerular Filtration Rate estimation. *Clin. J. Am. Soc.*



Nephrol. 6.

Wu, X., Xu, G., & Zhang, S. (2020). Association between cystatin C and cardiac function and long-term prognosis in patients with chronic heart failure. *Med. Sci. Monit.* 26 : 1–10.

Ziaecian, B., & Fonarow, G.C. (2016). Epidemiology and aetiology of heart failure. *Nat. Rev. Cardiol.* 13 : 368–378.